Foresite Capital Management IV, LLC Diversified Active

Name: Foresite Capital Management IV, LLC Q3 2023 13F Filing | 13F Explorer
Creator: Foresite Capital Management IV, LLC
Published: 2023-11-13

Location: West Hollywood, CA

CIK: 0001704132 · Show all filings

Period: Q3 2023 (← Previous) (Next →)

Filing Date: Nov 13, 2023

Total Value: $180M (100.0% shares, 0.0% debt)

Holdings (7)

PHVS Pharvaris N.V. 43.4%

Value $78.13M Shares 3,743,450 Est. Cost $28.56 Unrealized -35.5%

— Cymabay Therapeutics, Inc. 14.8%

Value $26.65M Shares 1,787,094 Est. Cost $3.49 Unrealized —

ACRS Aclaris Therapeutics, Inc. 10.7%

Value $19.24M Shares 2,808,034 Est. Cost $15.18 Unrealized -43.7%

KURA Kura Oncology, Inc. 9.4%

Value $16.87M Shares 1,849,947 Est. Cost $20.39 Unrealized -50.2%

— Kinnate Biopharma Inc. 7.5%

Value $13.54M Shares 9,671,643 Est. Cost $39.78 Unrealized —

— Lyell Immunopharma, Inc. 7.2%

Value $12.91M Shares 8,784,813 Est. Cost $16.24 Unrealized —

SNDX Syndax Pharmaceuticals, Inc. 7.1%

Value $12.71M Shares 875,000 Est. Cost $22.62 Unrealized -16.4%

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
PHVS	Pharvaris N.V.	3,743,450	$78.13M	43.4%	$28.56	-35.5%	COM	N69605108
—	Cymabay Therapeutics, Inc.	1,787,094	$26.65M	14.8%	$3.49	—	COM	23257D103
ACRS	Aclaris Therapeutics, Inc.	2,808,034	$19.24M	10.7%	$15.18	-43.7%	COM	00461U105
KURA	Kura Oncology, Inc.	1,849,947	$16.87M	9.4%	$20.39	-50.2%	COM	50127T109
—	Kinnate Biopharma Inc.	9,671,643	$13.54M	7.5%	$39.78	—	COM	49705R105
—	Lyell Immunopharma, Inc.	8,784,813	$12.91M	7.2%	$16.24	—	COM	55083R104
SNDX	Syndax Pharmaceuticals, Inc.	875,000	$12.71M	7.1%	$22.62	-16.4%	COM	87164F105